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Abstract. More than 60 years after their isolation and
characterization, aminoglycoside (AG) antibiotics remain
powerful agents in the treatment of severe gram-negative,
enterococcal or mycobacterial infections. However, the clinical
use of AGs is hampered by nephrotoxicity and ototoxicity,
which often develop as a consequence of prolonged courses of
therapy, or of administration of increased doses of these drugs.
The discovery of non-ototoxic antibacterial agents, showing
a wider spectrum of activity, has gradually decreased the use
of AGs as first line antibiotics for many systemic infections.
However, AGs are now undergoing an unexpected revival,
being increasingly indicated for the treatment of severe
emerging infections caused by organisms showing resistance
to most first-line agents (e.g., multidrug-resistant tuberculosis,
complicated nosocomially-acquired acute urinary tract
infections). Increasing adoption of aminoglycosides poses
again to scientists and physicians the problem of toxicity
directed to the kidneys and to the inner ear. In particular,
aminoglycoside-induced deafness can be profound and ir-
reversible, especially in genetically predisposed patients. For
this reason, an impressive amount of molecular strategies have
been developed in the last decade to counteract the ototoxic
effect of aminoglycosides. The present article overviews: i) the
molecular mechanisms by which aminoglycosides exert their
bactericidal activity, ii) the mechanisms whereby AGs exert
their ototoxic activity in genetically-predisposed patients, iii)
the drugs and compounds that have so far proven to prevent
or modulate AG ototoxicity at the preclinical and/or clinical
level, and iv) the dosage regimens that have so far been
suggested to decrease the incidence of episodes of AG-induced
ototoxicity.
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1. Aminoglycoside antibiotics: a revival?
Aminoglycoside (AG) antibiotics have been extensively used
for the prophylaxis and the treatment of a wide variety of
systemic infections, for the outstanding features displayed by
these antibacterial agents, i.e., the concentration-dependent
bactericidal activity, the post-antibiotic effect, the favorable
pharmacokinetic profile, and the strong synergism with other
antibiotics such as vancomycin and ß-lactams (1). More than
60 years after their isolation and characterization, these drugs
remain powerful tools for treatment of severe gram-negative,
enterococcal or mycobacterial infections. AGs are usually
administered in combination with ß-lactam antibiotics for a
variety of systemic infections (e.g., bacterial endocarditis or
various pseudomonal infections), but are also used as mono-
therapy for infections of the urinary tract. Streptomycin,
the first AG isolated and adopted for human therapy (Fig. 1),
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is still indicated for treatment of gentamicin-resistant entero-
coccal infections. Amikacin, one of the most widely adopted
members of the AG family, is useful against gentamicin-
resistant gram-negative organisms and in the treatment of
infections caused by nontuberculous mycobacteria. 
The clinical use of aminoglycosides has always been
hampered by nephrotoxicity and by the relatively high
incidence of severe ototoxicity, which often develops as a
consequence of prolonged courses of therapy, or after admin-
istration of increased doses of these agents. The discovery
of a number of non-ototoxic agents (e.g., fluoroquinolones),
characterized by a larger spectrum of antibacterial activity
and by optimal bioavailability following oral administration,
has gradually decreased the adoption of AGs as first-line
antibiotics for the treatment of a number of infectious
diseases. However, the emergence of severe, life-threatening,
drug resistant infections has recently restored a new interest
in AGs. 
At the time of its discovery by Schatz and Waksman
(1943) (2), streptomycin was used as the first available
antibiotic effective against Mycobacterium tuberculosis. AGs
were subsequently replaced by alternative antitubercular
drugs such as isoniazid, discovered in 1952, and rifampicin
(1963). In the last decade, highly-resistant, life-threatening
diseases, like multidrug-resistant tuberculosis (MDR-TB),
have compelled physicians and researchers to establish in a
very short time alternative therapeutic protocols. MDR-TB
occurs when the causative agent shows resistance to, at least,
isoniazid and rifampicin, two fundamental first-line compo-
nents of the standard therapeutic regimen for drug-susceptible
M. tuberculosis. In recommended therapeutic regimens, AGs
are always indicated for treatment of MDR-TB, in
combination with at least two other second-line anti-tubercular
agents. Suggested protocols for MDR-TB rank such agents
in order of importance as follows: i) aminoglycosides/
capreomycin and levofloxacin; ii) ethionamide/prothionamide
and ofloxacin/ciprofloxacin; iii) PAS; iv) cycloserine; v) ß-
lactams; vi) clarithromycin, linezolid and clofazimine (3).
Usually, long-term treatment (18-24 months) with a combi-
nation of ethambutol, pyrazinamide, a fluoroquinolone and
amikacin is indicated in the presence of resistance to isoniazid
and rifampicin, associated or not with resistance to strepto-
mycin (3).
Besides their increased use as antitubercular agents, AGs
are being indicated for the treatment of complicated urological
infections. Due to the almost complete renal excretion, AGs
are considered equivalent to first-choice antibacterial agents
in the eradication of urinary tract infections (1), and show
high efficacy in the treatment of complicated conditions (4),
including highly-resistant, nosocomially-acquired urinary
tract infections (NAUTI). A comprehensive, recent study on
hospital-acquired urinary tract infections in urology depart-
ments, analyzing the data from both the Pan-European
Prevalence and the Pan Euro-Asian Prevalence studies, has
shown that besides fluoroquinolones (adopted as first-choice
antibacterial agents, in 35% of cases), AGs are among the
most commonly prescribed drugs for treatment of NAUTI
(15% of cases), together with penicillins (16%) and 3rd
generation cephalosporins (14%) (5). In 2004, AGs were
recommended, in combination with ß-lactam antibiotics, for
the treatment of category I acute bacterial prostatitis by the
Chronic Prostatitis Collaborative Research Network, sponsored
by the National Institute of Diabetes and Digestive and
Kidney Diseases of the US National Institutes of Health (6).
Besides tuberculosis and complicated urinary tract infec-
tions, AGs are indicated for treatment of severe conditions
such as complicated bone or soft tissue infection, septicemia,
peritonitis and other severe intra-abdominal infections,
endocarditis, and neonatal sepsis.
AGs are usually active against common Gram-negative
uropathogens like E. coli, but also against specific Gram-
positive cocci, like Staphylococcus epidermidis. Enterococcus
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Figure 1. Molecular structures of streptomycin (A), paromomycin (B) and
gentamicin (C). R1 and R2 are substituents specific for gentamicin C1, C2
and C1a.
3-13  11/12/07  15:35  Page 4
faecalis, a very common Gram-positive uropathogen, is
resistant to AGs in ≤35% of hospital-based infections, but is
efficiently eradicated by aminoglycoside-ß lactam
combination therapy (7).
2. Bactericidal action of aminoglycosides
Aminoglycosides are multifunctional hydrophilic aminosugars
that are in most cases linked to a deoxystreptamine ring, and
possess several amino moieties which are usually protonated
in a physiological milieu. This confers to AGs the properties
of water-soluble weak bases at body pH, showing signi-
ficant affinity for nucleic acids, and in particular for the
16S ribosomal RNA (rRNA), in the 30S subunit of bacterial
ribosomes. 
16S rRNA is essential in selecting tRNAs and in catalyzing
peptide bond formation by ribosomes in prokaryotic cells.
It is known that high fidelity of translation is achieved by
the ability to discriminate between conformational changes
induced by binding of cognate or non-cognate tRNAs at the
aminoacyl-tRNA-binding ‘A’ site, in the decoding region of
the 16S rRNA. Aminoglycosides act as inhibitors of protein
synthesis because they increase the error rate of translation
by allowing erroneous pairing of non-cognate tRNAs.
2-deoxystreptamine aminoglycosides interact with the major
groove of the 16S rRNA helix H44. Two universally
conserved adenine residues (A1492 and A1493) in the rRNA
are directly involved in the decoding process during normal
translation. In the native structure of the ribosome, these
residues are stacked in the interior of helix 44 (‘off’
conformation). Binding of the tRNA to the A site causes the
displacement of both adenines out from their stacked position
(‘on’ conformation). This conformational change is necessary
for the specific directional interaction between A1492/1493
and two of three base pairs formed by the codon-anticodon
interaction. The N1 of these adenines interacts through a
hydrogen bond with the 2'OH in the mRNA codon, in the
first and second positions of the codon-anticodon triplet. In
this context, the pairing between cognate mRNAs and tRNAs
ensures appropriate interaction between the codon and the
ribosomal A site, whereas near-cognate tRNA and mRNA
interactions distort the structure of the codon-anticodon helix
and disrupts N1-OH contacts (8).
AGs like gentamicin and paromomycin (PM) (Fig. 1) can
bind the major groove of rRNA within a pocket generated by
Adenines 1408 and 1493 (Fig. 2), and a single bulged adenine
(A1492). Fig. 3 models the binding of paromomycin to the
A-site of 16S rRNA. An essential structural element for PM
and neomycin-class AG binding to 16S rRNA is the neamine
core, a two-ring system comprising a 2-deoxystreptamine
ring glycosylated at position 4 by a six-membered aminosugar
of the glycopyranoside series (Fig. 1). Binding of PM results
in the stabilization of adenines 1408, 1492 and 1493, and in
the flipping-out of the latter two; this can reduce the energetic
cost of codon-anticodon interactions, allowing binding of
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Figure 2. Sequence of the E. coli decoding region A site. The adenine
residue in position 1408 (base-paired with A1493) is highlighted.
Figure 3. Model of the binding pocket of paromomycin in the A site of bacterial 16S rRNA. The Connolly surface of the RNA is represented in blue.
Paromomycin is shown in red. Adenine 1408 and 1493 residues, creating a pocket for the binding of the aminoglycoside, are shown in green and in yellow,
respectively. This picture was generated with the PyMol software (http://pymol.org), based on the deposited structure (PDB ID: 1PBR) of the paromomycin-
rRNA complex (9).
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near-cognate or non-cognate tRNAs and causing in turn the
mistranslation of mRNA (9). For the implications in oto-
toxicity, it is necessary to underline that the C1409·G1491
base pair is essential for the antibacterial activity of some
aminoglycosides, since mutation or methylation of G1491
was found by Guan et al to generate bacterial resistance to
these antibiotics (10).
3. Hearing loss induced by aminoglycosides
Aminoglycosides are ototoxic when administered systemically
or locally, and affect initially high frequency hearing beyond
the range of normal speech. Thus, high frequency hearing loss
can be detected by audiometric testing, which can be utilized
to monitor AG-induced ototoxicity.
Renal impairment and pre-existing hearing loss can
increase the risk of toxicity of these antibiotics to the inner
ear. Moreover, the cumulative dose, the duration of treatment
and repeated courses of therapy are critical determinants of
toxicity at the level both of the kidneys and of the inner
ear. As far as topical toxicity is concerned, it is known that
AGs must not be prescribed for local administration in the
presence of lesions of the tympanic membrane, because they
can be readily absorbed through the fenestra rotunda, and can
rapidly exert their toxic activity at the cochlear and vestibular
levels.
Depending on their molecular structure, AG antibiotics
are characterized by enhanced tropism and selectivity for
different districts of the inner ear (11). Streptomycin (Fig. 1)
targets preferentially the vestibular portion of the inner ear.
Gentamicin, one of the most used AGs (Fig. 1), is also
prevalently vestibulotoxic in patients. Although vertigo and
balance problems tend to be only temporary due to subse-
quent compensation, impairment of the vestibular function
can persist and manifest through difficulty of walking in the
dark, or through the occurrence of the Dandy syndrome. In
about 4-15% of patients treated with 1 g/day streptomycin for
more than 7 days, hearing loss can also occur after a short
latency (7-10 days). The condition can worsen if treatment is
extended for longer periods. 
Neomycin is characterized by a more marked cochleotoxic
effect. Large doses of this drug, administered orally or locally
for pre-surgery colon irrigation, can be absorbed, especially
in the presence of ulcers and lesions within the GI mucosa.
Similarly, kanamycin, amikacin, tobramycin and netilmycin
(probably the least ototoxic members of the AG family) are
prevalently cochleotoxic (11). Viomycin appears to be both
cochleotoxic and vestibulotoxic.
Although hair cells in cristae, maculae or in the organ of
Corti are the primary targets of AGs (12), an interesting
study has demonstrated that cells in the stria vascularis, rich
in mitochondria and responsible for the maintenance of the
high potassium concentration of the endolymph (~157 mM,
generating a positive 80-90 mV potential relative to the peri-
lymph) (13), are targets of AGs like amikacin (14). However,
whereas the damage at the hair cell level can be permanent,
stria vascularis, if affected, is only transiently affected by
AGs (15). 
It is now evident that outer hair cells are more sensitive to
ototoxic injury than are inner hair cells. Aminoglycosides are
transported into hair cells, can be detected in perilymph
60-90 min after systemic administration, and remain detectable
in hair cells up to 4 months after exposure. In explants of inner
ears subjected to aminoglycosides or other ototoxic drugs, a
variety of reactive oxygen species can be detected, including
both oxygen and nitrogen free radicals. Free radical damage
to hair cells upon AG administration was shown to cause
ototoxicity in a variety of in vitro and in vivo models (12).
Recent findings by the Schacht group suggest that disruption
of the actin cytoskeleton induced by kanamycin in cochlear
sensory cells is mediated by Rac1 activation and the formation
of superoxide by NADPH oxidase. Free radicals may in turn
affect the RhoA/p140mDia gene pathway regulating actin,
and affect cell survival and apoptotic pathways, ultimately
resulting in loss of hair cells (16). 
4. Mutations predisposing to non-syndromic hearing loss
(NSHL) and aminoglycoside ototoxicity
Hearing loss can be caused by a variety of factors, and can be
sporadic, genetically transmitted or drug-induced. Genetically
transmitted hearing loss can be syndromic, i.e., combined with
other conditions, thus creating a complex picture of pathologic
alterations, or non-syndromic. In non-syndromic forms,
which occur in about 70% of cases of hereditary hearing loss,
deafness can be inherited by mitochondrial transmission, i.e.,
via the mother lineage.
A number of different genomic loci have been identified to
be responsible for NSHL (reviewed in refs. 17,18). The most
representative is DFNB1, responsible for over 50% of cases
of prelingual deafness. This locus contains the Gap Junction
Beta 2 (GJB2) gene, encoding connexin 26, a 26-kDa, 208-AA
protein (19). Within gap junction plaques, connexins associate
into hexamers, the connexons, forming juxtaposed inter-
cellular channels connecting the cytosol of adjacent cells,
allowing the exchange of ions and small molecules below a
molecular weight of about 1 kDa. DFNB1 on chromosome
13 is a major locus for recessive deafness in Mediterranean
affected families, and GJB2 is usually mutated in these
pedigrees (20).
Mutations in the mitochondrial genome linked to hearing
loss can be inherited or acquired, heteroplasmic or homo-
plasmic (reviewed in refs. 21,22). The most representative
deafness-linked mitochondrial mutations - at the level of
five distinct genes - are: i) A7445G (segregating with
palmoplantar keratoderma in some individuals), 7472insC
(associated with ataxia and/or focal myoclonus in some
individuals), T7510C and T7511C, located in or adjacent to
the tRNASer(UCN) gene; ii) A3243G, in the tRNAleu(UUR) gene
(can be associated with diabetes mellitus; 23,24); iii)
A8344G, in the tRNAlys gene; iv) T8993G, in the ATPase 6
gene; v) A827G, 961insC, 961delT/T961G (both associated
in some cases with aminoglycoside ototoxicity), T1005C,
T1095C, A1116G, T1291C, C1494T and A1555G, in the
gene encoding the 12S rRNA (25-29). Interestingly, whereas
in most cases of NSHL mutations are homoplasmic, all
mutations linked to syndromic hearing impairment have been
shown so far to be heteroplasmic.
The homoplasmic A1555G substitution, located in the
mitochondrial 12S ribosomal RNA gene, was the first mutation
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to be associated with non-syndromic hearing loss, but not
with vestibular alterations. It was identified by Prezant and
coworkers in the mother lineage of an Arab-Israeli pedigree,
whose members showed the appearance of severe to profound
sensorineural deafness during childhood or adulthood (30). In
carriers of this mutation hearing loss can arise spontaneously
or following exposure to aminoglycoside antibiotics (30). In
A1555G individuals, spontaneous deafness does not occur in
all carriers of this mutation, and intra- or inter-pedigree
penetrance variations are likely due to the contribution of
nuclear modifier genes. MTO1 is a gene responsible for tRNA
hypermodification, a process that conditions the efficiency
and accuracy of codon-anticodon interaction. This gene was
shown to be responsible for the phenotypic expression of
spontaneous deafness associated with the A1555G mutation
(31). 
A1555G is expected to be the most prevalent deafness-
linked mitochondrial mutation worldwide, having been
identified in both Caucasians and Asians as part of different,
unrelated haplogroups (21,23,24). It appears that the mutation
is more frequent in Asian populations (32), as the majority of
episodes of ototoxicity have been described in Chinese and
other Asian patients. However, it has to be taken into account
that aminoglycosides are more commonly prescribed - out of
hospital settings - in the Asian continent than in Western
European countries: this might mask an unsuspected higher
prevalence of the mutation in Europe and in European-descent
populations. It is however clear that the higher prevalence of
cases of ototoxicity in Asia is not due to variations in the
pharmacokinetic profile of AG antibiotics, which was shown
to be very similar in different populations (33). In the
Mediterranean area, a relatively high prevalence of the
A1555G mutation has been described. A study on Spanish
pedigrees reveals that the mutation accounts for about 15-20%
of analyzed familial cases of non-syndromic hearing loss,
irrespective of their mode of inheritance and age of onset (28).
Moreover, a phylogenetic analysis performed on 50 unrelated
Spanish families showed that the A1555G substitution may
have been generated by over 30 independent mutational events,
occurring in mitochondrial DNA (mtDNA) haplo-groups that
are found in all European populations. Indeed, the same
mutation has been identified in Italian families or in individuals
with Italian descent affected by aminoglycoside-induced or
spontaneous non-syndromic hearing loss (27,34,35). This
suggests that the mutation might show a significant prevalence
in patients affected by mitochondrial hearing loss in Italy,
together with the less frequent T1095C and A7445 mutations,
also described in Italian individuals and families (35,36).
As previously mentioned, the A1555G mutation is located
in the region of mitochondrial DNA encoding for the 12S
rRNA, a component of the 28S subunit of the mitochondrial
ribosome. It has been shown that the G variant of this mutation
can increase the affinity of aminoglycosides for the 12S rRNA
(37). The substitution of the adenine 1555 with a guanine
would allow the pairing with a corresponding cytosine 1494,
thus modifying the secondary structure of the RNA, at the
level of the stem of a specific stem-loop structure (Fig. 4).
Thus, the C1494-G1555 base pair in mitochondrial 12S rRNA
would mimic a critical C1409-G1491 pair, important for the
binding of specific AGs to the prokaryotic 16S rRNA in the
decoding region of the bacterial ribosome. In this way, the
binding of AGs to the 12S rRNA would be facilitated by the
conformational changes generated by the A1555G mutation.
This interaction is considered to be ultimately responsible for
the destruction of mitochondria and for the consequent damage
to hair cells at the cochlear level (38).
An additional mutation, C1494T, identified in the mtDNA
of a Chinese family, generates the A1555-T1494 base pair at
the same position (37). This mutation predisposes to amino-
glycoside-induced hearing loss, thus supporting a specific role
of this specific base pair as target of the toxic activity of AGs.
Fig. 4 shows the similarity between the highly conserved
aminoglycoside-binding regions of 16S bacterial and 12S
mitochondrial rRNAs, in the presence of the A1555G or
C1494T mutations.
5. Prevention and modulation of aminoglycoside-induced
ototoxicity
The findings described above imply that a proportion of
patients with aminoglycoside-induced ototoxicity harbor
mutations in the 12S rRNA gene. Drug-induced hearing loss
in these individuals could be easily prevented by investigation
of family history and by mitochondrial DNA analysis.
However, when administered at high doses or for prolonged
periods aminoglycosides can be toxic to the inner ear in
patients who do not bear known predisposing mutations. In
these cases, toxicity has been in most cases ascribed to inner
ear cell damage generated by oxygen free radicals and other
highly reactive molecules. In recent years, a number of
strategies have been identified and studied in vitro and in vivo
for the biochemical modulation and the chemoprevention of
AG ototoxicity. Most strategies are based on the administration
of antioxidants and other compounds that may counteract the
molecular and cellular damage caused by reactive oxygen
species. In the following section, a review of some of these
strategies is provided.
Drug/compound: Fosfomycin
Proposed mechanism of action. Fosfomycin inhibits the
accumulation of the AG dibekacin in the kidney, and reduces
its concentration in the kidney and in the serum. Reduction of
serum levels decreases the amount of AG delivered to the
inner ear.
Experimental evidence. Rats treated with 50 mg/kg dibekacin
combined with 500 mg/kg fosfomycin show markedly lower
levels of kidney and serum AG than animals receiving
dibekacin alone (39).
Drug/compound: Glutathione
Proposed mechanism of action. The damaging effects of the
aminoglycoside amikacin may be caused by a metabolite of
the drug. Glutathione acts as a source of cysteine, useful for
the metabolic detoxification of the metabolite. 
Experimental evidence. Guinea pigs treated with glutathione
in combination with amikacin show reduced damage to the
organ of Corti, compared to amikacin-only controls (40). In
the Garetz report (41), Guinea pigs were injected with 100 mg/
kg/day gentamicin. A group of animals received glutathione
by gastric gavage immediately prior to each gentamicin
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injection. Auditory brainstem responses revealed a progressive
gentamicin-induced hearing loss reaching a 30-40 dB threshold
shift at 2 kHz, approximately 60 dB at 8 kHz and 80 dB at
18 kHz. Glutathione significantly attenuated the final threshold
shifts by 20-40 dB. Morphological evaluation confirmed
hair cell loss after gentamicin treatment and protection by
glutathione.
Drug/compound: α-lipoic acid
Proposed mechanism of action. The compound can prevent the
cochlear toxicity following topic administration of neomycin
to the round window. α-lipoic acid is a free radical scavenger,
protecting the inner ear from damage induced by reactive
oxygen species. Among these, superoxide is generated by
drugs (including AGs) that cause a deficiency of mitochondrial
complex I (38).
Experimental evidence. Animals were implanted with osmotic
pumps delivering to the round window a solution containing
5% neomycin alone or in combination with 50 mg/ml
α-lipoic acid. Animals treated with combination therapy
experienced a decreased rate of deterioration of auditory
sensitivity (42).
Drug/compound: Leupeptin (calpain inhibitor); BAF (caspase
inhibitor)
Proposed mechanism of action. Inner ear hair cell death
following AG exposure was shown to be due to apoptosis.
Apoptosis is mediated by caspases and calpain. Caspase and
calpain inhibitors may prevent hair cell death by specific
enzymatic inhibition.
Experimental evidence. TUNEL-labeled cells showing apop-
totic DNA fragmentation were observed in the region of hair
cells exposed to 0.2 mM neomycin, in mouse cochlear explant
cultures. The caspase inhibitor BAF (200 μM) promoted
the survival of 50% of cells. The compound was not protec-
tive when higher AG doses were used (1 mM). Leupeptin
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Figure 4. Sequence similarity between bacterial (E. coli) 16S (top, left) and human mitochondrial 12S (top, right) rRNAs. Changes in the secondary structure
of the 12S rRNA are shown as a consequence of the A1555G (bottom, left) and C1494T (bottom, right) mutations. Highlighted bases in the 16S rRNA are
critical for binding of aminoglycosides. Base-pairing of the upper stem of the A site is not shown.
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(10 μg/ml) was significantly more efficient than BAF in
protecting hair cells from AG-induced apoptosis (43,44).
Drug/compound: Dexamethasone
Proposed mechanism of action. Reactive oxygen species
have shown to be generated by a metabolic by-product of
gentamicin. These species generate cell/tissue damage by
lipid peroxidation and DNA/protein damage. Dexamethasone
can counteract ROS formation by a mechanism that still has
to be fully studied.
Experimental evidence. Kanamycin (400 mg/kg) combined
with ethacrynic acid (40 mg/ml) was used to induce hair cell
death and a severe hearing loss (threshold shift: 80-100 dBSPL)
in Guinea pigs. Dexamethasone (1 ng/ml), delivered by
intracochlear administration with microcannulation osmotic
pumps, enhanced the auditory brainstem response (ABR),
and at higher doses (10 ng/ml) attenuated the damage to
outer hair cells (45).
Drug/compound: iron chelators [Deferoxamine (DFO), 2,3-
dihydroxybenzoate (DHB)]
Proposed mechanism of action. The ototoxic effects of genta-
micin require an active metabolite form of the drug. Metabolic
activation proceeds via the formation of a redoxactive iron-
gentamicin complex that catalyzes the production of oxygen-
free radicals. Agents that can prevent the formation of this
complex by titrating intracellular iron show protective
activity against cochlear and vestibular AG toxicity. Chu and
coworkers (46) have shown that DHB attenuates AG-induced
ototoxicity by enhancing the expression of the Na-K-2Cl
cotransporter-1 (NKCC1) in the marginal cells of the stria
vascularis and in type II fibrocytes in the inferior portion of
the spiral ligament. NKCC1 is responsible for the basolateral
uptake of potassium ions into stria vascularis cells from the
interatrial space. Potassium is then apically secreted by the
same cells into the endolymph, thus preserving the unique K+
concentration in this fluid. AG-generated free radicals are
responsible for the destruction of NKCC1.
Experimental evidence. In Guinea pigs, DHB (100 mg/kg/day)
attenuated a gentamicin-induced threshold shift of about
60 dB to approximately 10 dB, whereas DFO significantly
reduced the threshold to about 40 dB at 18 kHz (47). In
addition, DHB was efficient in fully protecting the vestibular
compartment from streptomycin-induced nystagmus. More-
over, DHB treatment affects molecular survival mechanisms
in hair cells (48). In the Conlon study, animals receiving
neomycin experienced elevation of elicited compound action
potential thresholds (CAP) of 37.5 dB at 2 or 4 kHz, and of
38.8 dB at 8 kHz. Animals treated with neomycin and
deferoxamine (150 mg/kg twice daily) maintained CAP-
elicited thresholds at all tested frequencies (49). In the study
of Sinswat et al (50), Guinea pigs were treated with 120 or
135 mg/kg gentamicin. Intraperitoneal administration of DHB
(100 mg/kg) attenuated the progressive hearing loss induced
by gentamicin (threshold shifts: 60 dB at 18 kHz) to less than
30 dB, and reduced the loss of hair cells.
Drug/compound: Salicylates
Proposed mechanism of action. As described above, AGs
catalyze the formation of free radicals through an iron-
dependent reaction. Salicylates act as iron chelators and
antioxidants, and protect against hearing loss. In addition,
salycilates (and DHB, see previous paragraph) can promote
the translocation of nuclear factor (NF)-κB into the nuclei of
outer hair cells, and thus prevent hair cell death by induction
of a specific survival pathway, as described by Jiang et al
(51).
Experimental evidence. Combination of gentamicin and
salicylates protected from an auditory threshold shift (>60-
20 dB) induced by gentamicin alone. Morphological assess-
ment showed protection of inner hair cells. The treatment did
not change gentamicin serum levels and was not detrimental
to the antibacterial activity of the drug (52).
Clinical evidence. A prospective, randomized, placebo-
controlled, double-blind clinical trial was conducted on a total
of 195 patients, aged 18-65, receiving total average doses of
about 980 mg gentamicin. Aspirin was administered in thrice-
daily doses of 1000 mg for 14 days. The total incidence of
hearing loss decreased from 13% in the gentamicin-only group
to 3% in the gentamicin/aspirin group; moderate hearing losses
(15-25 dB) decreased from 11 to 1%, respectively. Five patients
in the aspirin group reported gastric discomfort, and three were
excluded from the trial for gastric bleeding (53,54).
Drug/compound: Tanshinone [Saliae miltiorrhizae (Danshen)
extract]
Proposed mechanism of action. The diterpene quinone and
phenolic acid derivatives contained in S. miltiorrhizae
(Danshen) have antioxidant properties in vitro and in vivo, and
can act as scavengers of free radicals generated by metabolic
activation of aminoglycosides.
Experimental evidence. In vitro, Danshen inhibited gentamicin-
catalyzed formation of superoxide and hydroxy radicals, as
well as gentamicin-induced lipid peroxidation. In CBA mice
treated with 700 mg/kg gentamicin and various doses of
Danshen, attenuation of AG-induced auditory threshold shifts
(~50 dB) was documented (55).
Drug/compound: 4-methylcatechol
Proposed mechanism of action. AGs are toxic on spiral
ganglion neurons through a direct effect, but also indirectly,
by inducing the loss of neurotropic factors. 4-methylcatechol
protects spiral ganglion neurons by inducing the synthesis of
nerve growth factor.
Experimental evidence. The number of surviving spiral
ganglion neurons was significantly higher in mice treated
with gentamicin in combination with 4-methylcatechol than
in animals receiving the aminoglycoside alone (56).
Drug/compound: Concanavalin A
Proposed mechanism of action. Concanavalin A interferes
with the uptake of gentamicin into hair cells in vitro.
Experimental evidence. Postnatal rat cochlear explant cultures
were exposed to gentamicin with or without 100 mM con-
canavalin A. Significant protection was observed by confocal
microsopy only in hair cells co-exposed to concanavalin (57).
Drug/compound: Trimetazidine
Proposed mechanism of action. Protection from free-radical
injury.
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Experimental evidence. Swiss mice received gentamicin for
30 days, with or without trimetazidine. Auditory threshold
shifts were measured by evoked brain stem response, and
were found to be significantly different from controls in
animals receiving the AG. Conversely, threshold shifts in the
trimetazidine-gentamicin group were not significantly different
from control animals that did not receive the AG (58).
Drug/compound: Flavonoid fraction (FF) of Drynaria
fortunei
Experimental evidence. Guinea pigs were treated with 100 mg/
kg day gentamicin for two weeks. A group of animals was
pretreated with 10 mg/kg/day flavonoid fraction. The gen-
tamicin-only group showed a higher ABR threshold burst: 90,
92 and 72 dB at 2, 8 and 32 kHz, respectively, when compared
to the gentamicin+FF group (30, 37 and 38 dB) (59).
Drug/compound: basic fibroblast growth factor (FGF-2)
Experimental evidence. In neonatal rat organ of Corti cultures
inner hair cell survival and outer hair cell destruction (50% at
35 mM neomycin) was observed after neomycin administration
at micromolar concentrations. A protective effect was observed
when the same cultures were pretreated and co-exposed to
500 ng/ml FGF-2, with the exception of the effect of AGs on
disorganization of inner cell stereocilia (60).
Drug/compound: Transforming growth factor alpha (TGF-α)
Proposed mechanism of action. A rise in cell calcium levels
in hair cells of organ of Corti explants correlates with the
protection from aminoglycoside toxicity by exposure to
TGF-α.
Experimental evidence. 500 ng/ml TGF-α increases by 5-fold
the intracellular calcium concentration in hair cells (61).
Drug/compound: M40403
Proposed mechanism of action. M40403 is a manganese-based
molecule that mimics the activity of superoxide dismutase.
This molecule can protect inner hair cells from AG-induced
generation of reactive oxygen species by facilitating the
metabolism of superoxide radicals.
Experimental evidence. Inner and outer hair cells within
cochlear cultures from neonatal C57BL/10J mice were signi-
ficantly protected by low micromolar doses M30403 against
toxicity induced by gentamicin. However, 30 micro-molar
M30403 showed significant toxicity on the same cells.
Interestingly, the protective effect was not observed upon
exposure to ototoxic cisplatin (62).
Drug/compound: Argon
Proposed mechanism of action. Argon can protect neuronal
cells from hypoxic damage. 
Experimental evidence. Organotypic newborn rat organs of
Corti cultures exposed to Argon-oxygen mixtures (21% O2,
5% CO2, 74% Ar) were protected against the toxic activity of
5-40 micromolar gentamicin or 7-25 micromolar cisplatin (63).
Drug/compound: D-methionine
Proposed mechanism of action. D-methionine is an amino-acid
showing anti-oxidant and iron-chelating properties and protects
from AG-induced generation of free radicals (see above). 
Experimental evidence. Threshold shifts induced by 120 mg/kg
gentamicin (40 dB at 3 kHz; 50-60 dB at 18 kHz) were
significantly reduced at all frequencies when D-methionine
was co-administered at the twice-daily dose of 200 mg/kg.
D-methionine (30 mM) also was effective in reducing the
gentamicin-induced generation of free radicals in EBV-
transformed lymphoblastoid cells (64).
Drug/compound: fusion protein TAT-FNK
Proposed mechanism of action. FNK was constructed by
introducing amino-acid substitutions into the Bcl-XL anti-
apoptotic protein, creating a mutant with a gain-of-function
phenotype, showing higher anti-apoptotic activity to protect
cultured cells from death induced by various stimuli, including
oxidative stress and AG-induced toxicity to hair cells of the
inner ear. When fused to the TAT protein transduction domain
of the HIV/TAT protein, FNK is readily introduced into target
cells, where it can exert its protective function against AG-
induced damage.
Experimental evidence. TAT-FNK attenuated cochlear damage
induced by 200-400 mg/kg kanamycin, administered in combi-
nation with ethacrynic acid to Guinea pigs. Auditory brainstem
response threshold shifts induced by kanamycin were markedly
attenuated in animals treated with TAT-FNK. A protective
activity by TAT-FNK against AG-induced apoptosis was also
demonstrated by the reduction of cleaved poly-(ADP-ribose)
polymerase in hair cells 8 hours after AG administration (65).
Drug/compound: MK801 (N-methyl-D-Aspartate antagonist);
neurotrophin 3 (NT3)
Proposed mechanism of action. In the peripheral auditory
system, the excitatory neurotransmitter glutamate acts by
binding the N-methyl-D-Aspartate (NMDA) receptor, located
on the terminals of the spiral ganglion neurons. Cell death by
excitotoxicity is caused by a calcium overload induced by
overstimulated NMDA receptors. AGs mimic the effect of
polyamines on the NMDA receptor and cause excitotoxicity.
The NMDA antagonist MK801 can counteract this effect.
NT3 cooperates by promoting survival of auditory neurons.
Experimental evidence. In amikacin-treated (300 mM
administered by osmotic pumps) Guinea pigs, combined
treatment of MK801 (1 mg/kg/day X 3, i.p.) and NT3 (300 ng/h
for 24 h) caused partial protection of hair cells (≥50% cell
survival vs. 0% in amikacin-only group) and complete
protection of spiral ganglion neurons (103% survival vs.
10.4% in amikacin-only group); moreover, auditory brainstem
response threshold shifts were significantly decreased, and
remained within 20 dB of normal values (66-68).
Drug/compound: non-ototoxic doses of the aminoglycoside
amikacin
Proposed mechanism of action. As described in previous
sections, aminoglycosides can chelate iron and form ototoxic
metabolites; these complexes generate free oxygen radicals
that in turn cause hair cell damage. A subtoxic dose of AG
may cause a gradual ‘preparation’ of these cells for ‘self-
defence’, likely by increasing the levels of anti-free radical
agents like glutathione. It should be remarked that a pre-
treatment with low dose aminoglycosides is possible only in
laboratory conditions. Patients diagnosed with infectious
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diseases cannot be treated with ineffective low doses of
antibiotics, because therapy has to commence immediately.
Furthermore, a low-dose treatment with aminoglycosides
would increase the bacterial resistance, thus being counter-
productive to an effective therapy.
Experimental evidence. When a group of Guinea pigs treated
with 400 mg/kg amikacin for 12 days was compared to animals
pre-treated with low-doses of the drug (20 mg/kg for 30 days
followed by 400 mg/kg for 12 days), the conservation of outer
hair cells was found to be significantly higher in the latter
group, especially in the more basal turns of the cochlea (69).
Drug/compound: α-phenyl-tert-butyl-nitrone (PBN)
Proposed mechanism of action. PBN acts as a scavenger of
free radicals generated by metabolic activation of AGs.
Experimental evidence. Guinea pigs were monitored for
compound action potentials thresholds. Animals were subjectd
to treatment with 60 mg/kg PBN, followed by application of
PBN to the round window membrane, and by local application
of AG. This protocol significantly decreased the compound
action potential threshold sensitivity loss observed in the
presence of the aminoglycoside alone (70).
6. Dose and regimen optimization
Due to their pharmacokinetic/pharmacodynamic properties,
aminoglycosides may be administered using flexible dosing
regimens. In addition to traditional medium-term, twice/thrice-
daily parenteral administration, single-daily dosing (SDD)
or switch-therapy regimens have been adopted as effective
therapeutic strategies. 
In particular, due to the long urinary half-life of AGs
(>100 h, with a 3-compartment modeled distribution), single-
daily dosing regimens have been shown to be effective in the
treatment of severe urological conditions like pyelonephritis
(7). Since over a decade, a number of preclinical and clinical
studies have been performed to compare the effectiveness and
tolerability of SDD vs. multiple daily dosing (MDD) of AGs.
Although not recommended for pediatric patients, SDD is
believed to evoke increased bactericidal effects due to higher
peak serum levels, decreased emergence of resistant organisms,
longer post-antibiotic effect and increased time lag for
resolution of adaptive resistance. Animal studies and a meta-
analysis of clinical trials have shown that single daily dosing
(e.g. 5-7 mg/kg every 24 h) of AGs is less ototoxic than
MDD (reviewed in ref. 7). However, other meta-analyses did
not demonstrate differential toxicity between the two dosing
regimens. A switch therapy regimen based on a single large
daily dose of gentamicin (10 mg/kg), followed by twice-daily
ciprofloxacin (250 mg) for five days, has been compared to a
multiple dose aminoglycoside-ciprofloxacin protocol in the
context of a prospective, randomized controlled clinical trial
which included 53 acute pyelonephritis patients. It was
demonstrated that the former regimen induced ototoxicity in
17% of cases, whereas the latter showed a higher rate (30%) of
hearing impairment episodes (71). This was likely due to the
combined effects of the single-dose strategy and the switch to
a non-ototoxic antibacterial agent. Interestingly, the two
regimens were equally effective in eradicating the causative
agents of pyelonephritis.
It seems paradoxical that, although SDD induces higher
peak serum concentrations, lower ototoxicity is observed
when compared to MDD. However, it is known that inner ear
uptake of AGs is a saturation process. According to Santucci
and Krieger, with SDD inner ear cells are saturated only
once, whereas with MDD saturation occurs 2-3 times within
24 h (7), thus increasing the cellular aminoglycoside load.
7. Conclusions
Damage caused by reactive oxygen species on hair cells was
shown to be a general mechanism of AG ototoxicity. In
genetically predisposed individuals, AGs target the mito-
chondrial 12S ribosomal RNA, and likely disrupt mitochondria
by affecting translation in a fashion resembling their
bactericidal activity. However, in carriers of mutations at the
mitochondrial level, free radicals may also play an important
role in inner ear cell disruption, since generation of reactive
oxygen species by defective oxidative phosphorylation may
be due to mistranslation or altered expression of mito-
chondrial proteins involved in this process, caused in turn by
inherited mutations in rRNA-encoding sequences.
An impressive amount of pharmacological and molecular
strategies have been developed to counteract the toxic effect of
aminoglycosides in the inner ear in non-genetically predisposed
individuals. However, these data have been obtained in pre-
clinical settings, and extensive clinical trials will be necessary
to validate the above-described evidence, given that potentially
protective drugs should be non-toxic to the patient by systemic
administration, should not lower aminoglycoside serum levels,
and should not interfere with the antibacterial activity of the
drugs.
As summarized above, in a recent double-blind, placebo-
controlled clinical trial it was shown that administration of
acetylsalicylic acid can significantly attenuate the risk of
gentamicin-induced hearing loss (53). Due to the convincing
clinical and preclinical data, and to the fact that the proposed
protocol is simple and cost-effective, aspirin is likely to be
further investigated for adoption as an oto-protective agent in
the clinical practice. In particular, it would be interesting to
ascertain whether dose reduction may decrease the episodes
of gastric intolerance without affecting the protective potential
of the drug. However, the suggested dose of 3 g/day is currently
authorized for treatment of rheuma patients (2-4 g/day); to
decrease the incidence of episodes of gastric intolerance
aspirin could be administered in the form of enteric-coated
tablets, with particular caution on the potential adverse
effects in sensitive individuals. 
As shown in the articles and reviews cited herein, extensive
research has been performed to characterize the mechanisms
whereby aminoglycosides exert their ototoxic activity, and
to discover new agents or new dosing regimens aimed at
minimizing these effects. If correctly validated and applied,
some of the evidence will surely be beneficial to patients and
useful to clinicians, and will allow a more extensive and safer
use of these old, yet potent antimicrobial agents.
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